Amgen Inc (AMGN) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amgen Inc. (AMGN) has completed a Phase 1/2 study titled “A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors.” The study aims to find a safe dose range and early signs of benefit in hard-to-treat MTAP-null cancers, a niche where new options are limited.
The trial tested two oral drugs, Anvumetostat (also known as AMG 193) and IDE397. The drug pair is designed to target a specific weakness in MTAP-null tumors and may offer a more focused approach than standard chemotherapy if results prove positive.
This was an interventional study in two parts, with no placebo group and no blinding. Doses were first escalated to find the best tolerated combination and then expanded in more patients to explore safety and early activity, with the primary goal of treating advanced MTAP-null solid tumors and MTAP-null non-small-cell lung cancer.
The study was first submitted in July 2023, marking its formal launch on the ClinicalTrials platform. The latest update was filed on April 21, 2026, confirming that the trial status is now “completed,” which signals that data collection is finished and analysis can move toward potential disclosure.
For investors, completion of this early-stage study is an important signal rather than a direct value driver. AMGN’s near-term stock impact will depend on whether safety looks manageable and whether any early tumor responses justify larger trials, especially in comparison with other precision oncology players like IDEAYA and larger rivals in targeted lung cancer.
The update may support long-term sentiment around Amgen’s innovation pipeline if forthcoming data are supportive, but it does not yet change earnings forecasts or commercialization timelines. The study is now completed and recently updated, with further details available on the ClinicalTrials portal.
To learn more about AMGN’s potential, visit the Amgen Inc drug pipeline page.